Tearsheet

Stryker (SYK)

Market Price (11/2/2025): $356.26 | Market Cap: $136.2 Bil
Sector: Health Care | Industry: Health Care Equipment

Stryker (SYK)

Market Price (11/2/2025): $356.26
Market Cap: $136.2 Bil
Sector: Health Care
Industry: Health Care Equipment

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Attractive operating margins Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 20%	Weak multi-year price returns 2Y Excs Rtn is -28%, 3Y Excs Rtn is -18%	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 28x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 28x, P/EPrice/Earnings or Price/(Net Income) is 46x
1	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17%, CFO LTM is 4.8 Bil, FCF LTM is 4.1 Bil
2	Low stock price volatility Vol 12M is 22%

0	Attractive operating margins Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 20%
1	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17%, CFO LTM is 4.8 Bil, FCF LTM is 4.1 Bil
2	Low stock price volatility Vol 12M is 22%
3	Weak multi-year price returns 2Y Excs Rtn is -28%, 3Y Excs Rtn is -18%
4	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 28x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 28x, P/EPrice/Earnings or Price/(Net Income) is 46x

Market Valuation & Key Metrics

	11/2/25	2024	2023	2022	2021
Share Price CYE	$356.26	$357.64	$294.74	$238.07	$257.15
Market Cap CYE ($ Bil)	136.2	136.4	112.0	90.1	97.1
Total Debt ($ Bil)	16.6	13.6	13.0	13.0	12.5
Total Cash ($ Bil)	3.3	4.5	3.1	1.9	3.0
Enterprise Value ($ Bil)	149.5	150.0	125.0	103.1	109.6
Valuation Ratios
P/S TTM	5.6	6.1	5.5	5.0	5.9
P/EBIT TTM	28.5	29.4	29.0	29.7	37.5
P/E TTM	46.3	45.8	35.9	39.2	50.6
Sector Ratios
P/S TTM (Sector)	4.1	3.5	4.0	4.5	7.3
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4	-1.3	-2.7
P/E TTM (Sector)	-2.0	-1.5	-1.5	-1.3	-2.8

	11/2/25	2024	2023
Share Price CYE	$356.26	$357.64	$294.74
Market Cap CYE ($ Bil)	136.2	136.4	112.0
Total Debt ($ Bil)	16.6	13.6	13.0
Total Cash ($ Bil)	3.3	4.5	3.1
Enterprise Value ($ Bil)	149.5	150.0	125.0
Valuation Ratios
P/S TTM	5.6	6.1	5.5
P/EBIT TTM	28.5	29.4	29.0
P/E TTM	46.3	45.8	35.9
Sector Ratios
P/S TTM (Sector)	4.1	3.5	4.0
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4
P/E TTM (Sector)	-2.0	-1.5	-1.5

	SYK	S&P 500
REVENUE GROWTH	GOOD
Rev LTM ($ Bil)	24.4
Rev Chg Q	10.2%	6.6%
Rev Chg LTM	11.0%	5.4%
Rev Chg 3Y Avg	10.8%	5.3%
PROFITABILITY	FAIR
Op Inc LTM ($ Bil)	4.8
CFO LTM ($ Bil)	4.8
Net Inc LTM ($ Bil)	2.9
Op Mgn LTM	19.6%	18.7%
CFO/Rev LTM	19.8%	20.3%
Net Inc Mgn	12.1%	12.8%
VALUATION	VERY HIGH
P/S	5.6	3.2
P/CFO	28.2	15.1
P/FCF	33.4	20.4
P/E	46.3	23.6
STABILITY	GOOD
Debt/Equity	0.12	0.21
Cash/Assets	0.07	0.07

AI Generated Analysis | Feedback

Metric	Date	Source
Operating Profit Margin	-	Link
Net Profit Margin	-	Link
Net Sales- Orthopaedics and Spine- Knees- United States	-	Link
Net Sales- Orthopaedics and Spine- Hips- United States	-	Link
Net Sales- MedSurg and Neurotechnology	-	Link
Net Sales- Orthopaedics and Spine	-	Link
Net Sales- Other Orthopaedics and Spine- Total	-	Link
Net Sales- Orthopaedics and Spine- Trauma and Extremities	-	Link
Net Sales by Geography- International	-	Link
Net Sales by Geography- United States	-	Link
Net Sales by Geography- Orthopaedics	-	Link
Net Sales by Business- MedSurg and Neurotechnology	-	Link
Net Sales by Geography- Orthopaedics- Other	-	Link
Net Sales by Geography- Orthopaedics- United States	-	Link
Net Sales by Geography- Orthopaedics- Trauma and Extremities- United States	-	Link

SYK Stock

Stock Price
Market Cap

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Generated Analysis | Feedback

null

Stock Movement Drivers

Fundamental Drivers

The -5.5% change in SYK stock from 8/2/2025 to 11/1/2025 was primarily driven by a -6.2% change in the company's P/E Multiple.

	8022025	11012025	Change
Stock Price ($)	376.93	356.24	-5.49%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	23818.00	24381.00	2.36%
Net Income Margin (%)	12.25%	12.07%	-1.47%
P/E Multiple	49.37	46.29	-6.24%
Shares Outstanding (Mil)	382.20	382.40	-0.05%
Cumulative Contribution			-5.49%

LTM = Last Twelve Months as of date shown

Market Drivers

8/2/2025 to 11/1/2025

	Return	Correlation
SYK	-5.5%
Market (SPY)	9.7%	20.3%
Sector (XLV)	10.0%	46.0%

Fundamental Drivers

The -5.4% change in SYK stock from 5/3/2025 to 11/1/2025 was primarily driven by a -7.9% change in the company's P/E Multiple.

	5032025	11012025	Change
Stock Price ($)	376.56	356.24	-5.40%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	23218.00	24381.00	5.01%
Net Income Margin (%)	12.31%	12.07%	-1.97%
P/E Multiple	50.27	46.29	-7.93%
Shares Outstanding (Mil)	381.70	382.40	-0.18%
Cumulative Contribution			-5.40%

LTM = Last Twelve Months as of date shown

Market Drivers

5/3/2025 to 11/1/2025

	Return	Correlation
SYK	-5.4%
Market (SPY)	20.7%	45.3%
Sector (XLV)	4.6%	52.0%

Fundamental Drivers

The -2.1% change in SYK stock from 11/1/2024 to 11/1/2025 was primarily driven by a -26.1% change in the company's Net Income Margin (%).

	11012024	11012025	Change
Stock Price ($)	363.85	356.24	-2.09%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	21974.00	24381.00	10.95%
Net Income Margin (%)	16.34%	12.07%	-26.12%
P/E Multiple	38.62	46.29	19.84%
Shares Outstanding (Mil)	381.10	382.40	-0.34%
Cumulative Contribution			-2.09%

LTM = Last Twelve Months as of date shown

Market Drivers

11/1/2024 to 11/1/2025

	Return	Correlation
SYK	-2.1%
Market (SPY)	20.6%	63.3%
Sector (XLV)	-1.1%	61.0%

Fundamental Drivers

The 73.1% change in SYK stock from 11/2/2022 to 11/1/2025 was primarily driven by a 46.1% change in the company's P/E Multiple.

	11022022	11012025	Change
Stock Price ($)	205.77	356.24	73.13%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	17948.00	24381.00	35.84%
Net Income Margin (%)	13.69%	12.07%	-11.82%
P/E Multiple	31.69	46.29	46.07%
Shares Outstanding (Mil)	378.40	382.40	-1.06%
Cumulative Contribution			73.11%

LTM = Last Twelve Months as of date shown

Market Drivers

11/2/2023 to 11/1/2025

	Return	Correlation
SYK	30.4%
Market (SPY)	62.0%	53.9%
Sector (XLV)	17.1%	58.6%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
SYK Return	18%	10%	-7%	24%	21%	3%	93%
Peers Return	4%	-2%	-7%	8%	3%	-1%	5%
S&P 500 Return	16%	27%	-19%	24%	23%	16%	112%
Monthly Win Rates [3]
SYK Win Rate	67%	67%	50%	67%	58%	44%
Peers Win Rate	43%	40%	37%	40%	38%	60%
S&P 500 Win Rate	58%	75%	42%	67%	75%	70%
Max Drawdowns [4]
SYK Max Drawdown	-40%	-10%	-29%	0%	-2%	-6%
Peers Max Drawdown	-29%	-9%	-18%	-9%	-6%	-12%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: JNJ, MDT, ZBH, ITGR, CUPR. See SYK Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/31/2025 (YTD)

How Low Can It Go

Unique Key	Event	SYK	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-32.4%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	48.0%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	199 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-43.8%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	77.9%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	203 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-19.3%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	24.0%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	44 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-59.2%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	145.2%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	1766 days	1480 days

Compare to JNJ, MDT, ZBH, ITGR, CUPR

In The Past

Stryker's stock fell -32.4% during the 2022 Inflation Shock from a high on 9/8/2021. A -32.4% loss requires a 48.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Stryker (SYK)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

Better Bets than Stryker (SYK)

	SYK	Better Performance than SYK
Metric	Value	Industry (Health Care Equipment)
Rev Chg LTM	11.0%	ISRG (22.2%), BSX (21.4%), PODD (26.0%), PEN (12.9%), GMED (17.4%)
Rev Chg 3Y Avg	10.8%	ISRG (16.3%), BSX (14.6%), RMD (13.3%), DXCM (17.3%), PODD (26.1%)
Op Mgn LTM	19.6%	ISRG (29.3%), IDXX (31.1%), EW (27.9%), RMD (33.5%), LMAT (23.3%)
CFO/Rev LTM	19.8%	ABT (20.8%), ISRG (30.8%), BSX (23.2%), MDT (20.9%), IDXX (22.4%)
FCF/Rev LTM	16.7%	ISRG (23.6%), BSX (17.5%), IDXX (19.2%), RMD (33.4%), ZBH (17.7%)
Total Yield	3.1%	ABT (8.4%), MDT (7.1%), BDX (5.4%), EW (8.6%), RMD (4.9%)

	SYK	Better Performance than SYK
Metric	Value	Sector (Health Care)
Rev Chg LTM	11.0%	LLY (36.8%), ISRG (22.2%), AMGN (12.9%), BSX (21.4%), PFE (13.5%)
Rev Chg 3Y Avg	10.8%	LLY (23.4%), UNH (11.4%), ISRG (16.3%), BSX (14.6%), VRTX (11.0%)
Op Mgn LTM	19.6%	LLY (43.0%), JNJ (26.2%), ABBV (23.5%), MRK (31.2%), ISRG (29.3%)
CFO/Rev LTM	19.8%	LLY (20.5%), JNJ (26.3%), ABBV (33.1%), MRK (29.1%), ABT (20.8%)
FCF/Rev LTM	16.7%	JNJ (20.3%), ABBV (31.3%), MRK (23.1%), ISRG (23.6%), AMGN (30.4%)
Total Yield	3.1%	JNJ (8.2%), ABBV (3.9%), UNH (8.2%), MRK (11.3%), ABT (8.4%)

	SYK	Better Performance than SYK
Metric	Value	All Other Sectors
Rev Chg LTM	11.0%	NVDA (71.6%), MSFT (15.6%), GOOGL (13.4%), AVGO (28.0%), META (21.3%)
Rev Chg 3Y Avg	10.8%	NVDA (92.0%), MSFT (13.2%), GOOGL (11.0%), AMZN (11.3%), AVGO (24.0%)
Op Mgn LTM	19.6%	NVDA (58.1%), AAPL (31.9%), MSFT (46.3%), GOOGL (32.2%), AVGO (39.0%)
CFO/Rev LTM	19.8%	NVDA (46.6%), AAPL (26.6%), MSFT (50.0%), GOOGL (39.3%), AVGO (42.4%)
FCF/Rev LTM	16.7%	NVDA (43.6%), AAPL (23.5%), MSFT (26.6%), GOOGL (19.1%), AVGO (41.6%)
Total Yield	3.1%	MSFT (3.4%), GOOGL (3.9%), META (3.9%), JPM (6.5%), WMT (3.5%)

		Best Bets In Health Care Sector
	SYK	RPRX	HALO	CPRX	BMY	LNTH	PBH	MRK	BIIB	PFE	EW
What You Pay
P/E	46.3	15.6	14.2	12.5	15.5	14.6	14.1	13.2	14.1	13.0	11.7
P/EBIT	28.5	8.2	11.1	10.7	9.4	10.0	9.0	10.6	10.5	10.5	28.9
What You Get
Rev Chg Q	10.2%	7.7%	40.8%	19.4%	2.8%	-4.1%	-6.6%	-1.9%	2.8%	10.3%	11.9%
Rev Chg LTM	11.0%	3.0%	35.0%	28.5%	1.3%	5.7%	0.6%	1.8%	4.8%	13.5%	9.1%
Rev Chg 3Y Avg	10.8%	0.8%	35.5%	49.9%	1.0%	34.3%	0.8%	3.7%	-0.9%	-12.4%	3.0%
FCF/Rev 3Y Avg	14.7%	113.4%	43.4%	38.9%	29.0%	26.1%	21.6%	20.9%	17.0%	13.8%	11.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic	Date
0	DASHBOARDS
1	Stryker Earnings Notes
2	How Low Can Stryker Stock Really Go?	Return
3	Stryker vs Microsoft: Which Is A Better Investment?	Counter-Intuitive Comparisons
4	Stryker vs Eli Lilly: Which Is A Better Investment?	Counter-Intuitive Comparisons
5	SYK Testing Price Floor: Time to Load Up?	Actionable
6	Wait For A Dip To Buy Stryker Stock	Buy or Fear
7	How Does Stryker Stock Stack Up Against Its Peers?	Peer Comparison
8	Better Bet Than SYK Stock: Pay Less Than Stryker To Get More From META, LLY
9	Better Bet Than SYK Stock: Pay Less Than Stryker To Get More From LLY, MCK
10	Better Bet Than SYK Stock: Pay Less Than Stryker To Get More From GMED
11	ARTICLES
12	SYK Hits Key Support – Is This The Buying Opportunity?		August 15th, 2025
13	Wait for a dip to buy Stryker stock		August 14th, 2025
14	Better Bet Than Stryker Stock: Pay Less To Get More From GMED, UFPT		August 2nd, 2025
15	S&P 500 Stocks Trading At 52-Week High		July 24th, 2025
16	Better Bet Than Stryker Stock: Pay Less To Get More From GMED, UFPT		July 23rd, 2025

	Title
0	DASHBOARDS
1	SYK Hits Key Support – Is This The Buying Opportunity?
2	Wait for a dip to buy Stryker stock
3	Better Bet Than Stryker Stock: Pay Less To Get More From GMED, UFPT
4	S&P 500 Stocks Trading At 52-Week High
5	Better Bet Than Stryker Stock: Pay Less To Get More From GMED, UFPT
6	ARTICLES
7	Stryker Earnings Notes
8	How Low Can Stryker Stock Really Go?
9	Stryker vs Microsoft: Which Is A Better Investment?
10	Stryker vs Eli Lilly: Which Is A Better Investment?
11	SYK Testing Price Floor: Time to Load Up?
12	Wait For A Dip To Buy Stryker Stock
13	How Does Stryker Stock Stack Up Against Its Peers?
14	Better Bet Than SYK Stock: Pay Less Than Stryker To Get More From META, LLY
15	Better Bet Than SYK Stock: Pay Less Than Stryker To Get More From LLY, MCK
16	Better Bet Than SYK Stock: Pay Less Than Stryker To Get More From GMED

Trade Ideas

Select past ideas related to SYK. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
GDRX_10312025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	10312025	GDRX	GoodRx	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	0.0%	0.0%	0.0%
DXCM_10312025_Monopoly_xInd_xCD_Getting_Cheaper	10312025	DXCM	DexCom	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	0.0%	0.0%	0.0%
ACHC_10242025_Dip_Buyer_ValueBuy	10242025	ACHC	Acadia Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	-8.1%	-8.1%	-8.1%
PBH_10102025_Dip_Buyer_ValueBuy	10102025	PBH	Prestige Consumer Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	-0.7%	-0.7%	-1.2%
REGN_10032025_Dip_Buyer_ValueBuy	10032025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	8.6%	8.6%	-7.0%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
GDRX_10312025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	10312025	GDRX	GoodRx	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	0.0%	0.0%	0.0%
DXCM_10312025_Monopoly_xInd_xCD_Getting_Cheaper	10312025	DXCM	DexCom	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	0.0%	0.0%	0.0%
ACHC_10242025_Dip_Buyer_ValueBuy	10242025	ACHC	Acadia Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	-8.1%	-8.1%	-8.1%
PBH_10102025_Dip_Buyer_ValueBuy	10102025	PBH	Prestige Consumer Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	-0.7%	-0.7%	-1.2%
REGN_10032025_Dip_Buyer_ValueBuy	10032025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	8.6%	8.6%	-7.0%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	BFLY	Butterfly Network	31.9%	-13.8%
2	BHF	Brighthouse Financial	24.9%	18.8%
3	ILMN	Illumina	24.8%	-7.6%
4	GDYN	Grid Dynamics	22.9%	-58.0%
5	ARDX	Ardelyx	21.0%	19.5%
6	PACB	Pacific Biosciences of California	20.6%	27.9%
7	TWLO	Twilio	19.5%	24.8%
8	TVTX	Travere Therapeutics	18.6%	101.8%
9	BJRI	BJ's Restaurants	18.4%	-3.3%
10	BFAM	Bright Horizons Family Solutions	18.4%	-1.5%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	ATGE	Adtalem Global Education	-30.9%	7.9%
2	SVV	Savers Value Village	-30.4%	-10.1%
3	NWL	Newell Brands	-28.0%	-64.6%
4	SPSC	SPS Commerce	-20.8%	-55.3%
5	SOC	Sable Offshore	-18.5%	-54.3%
6	CPS	Cooper-Standard	-15.5%	122.9%
7	TBBK	Bancorp	-15.3%	24.2%
8	DXCM	DexCom	-14.6%	-25.1%
9	KOD	Kodiak Sciences	-13.9%	82.2%
10	AAUC	Allied Gold	-12.8%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	PUMP	ProPetro	64.5%	11.3%
2	VTYX	Ventyx Biosciences	46.8%	289.5%
3	INBX	Inhibrx Biosciences	42.5%	430.3%
4	RNA	Avidity Biosciences	42.1%	140.2%
5	GCI	Gannett	40.6%	4.7%
6	CSIQ	Canadian Solar	38.4%	86.7%
7	DYN	Dyne Therapeutics	31.9%	-4.2%
8	ZBIO	Zenas BioPharma	30.8%	281.6%
9	IMVT	Immunovant	30.3%	-0.4%
10	BBNX	Beta Bionics	29.9%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	LRN	Stride	-55.3%	-34.5%
2	NTLA	Intellia Therapeutics	-50.7%	8.2%
3	FMC	FMC	-50.2%	-67.4%
4	FI	Fiserv	-46.7%	-67.5%
5	VRNS	Varonis Systems	-43.5%	-20.7%
6	ATGE	Adtalem Global Education	-35.9%	7.9%
7	UAMY	United States Antimony	-32.8%	355.9%
8	SVV	Savers Value Village	-31.7%	-10.1%
9	NWL	Newell Brands	-31.7%	-64.6%
10	AKBA	Akebia Therapeutics	-27.1%	16.3%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PRAX	Praxis Precision Medicines	260.1%	158.3%
2	VTYX	Ventyx Biosciences	141.6%	289.5%
3	INBX	Inhibrx Biosciences	132.9%	430.3%
4	TMQ	Trilogy Metals	112.9%	283.6%
5	REPL	Replimune	109.2%	-19.7%
6	PUMP	ProPetro	93.3%	11.3%
7	VICR	Vicor	85.6%	87.8%
8	DYN	Dyne Therapeutics	79.9%	-4.2%
9	GLUE	Monte Rosa Therapeutics	68.4%	85.2%
10	NVTS	Navitas Semiconductor	64.2%	277.0%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	LRN	Stride	-53.2%	-34.5%
2	FMC	FMC	-51.7%	-67.4%
3	FI	Fiserv	-47.0%	-67.5%
4	SOC	Sable Offshore	-46.5%	-54.3%
5	VRNS	Varonis Systems	-40.8%	-20.7%
6	OGN	Organon	-38.3%	-53.7%
7	NTLA	Intellia Therapeutics	-38.3%	8.2%
8	VG	Venture Global	-37.8%
9	ITGR	Integer	-37.4%	-51.3%
10	NWL	Newell Brands	-34.7%	-64.6%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	BFLY	Butterfly Network	31.9%	-13.8%
2	BHF	Brighthouse Financial	24.9%	18.8%
3	ILMN	Illumina	24.8%	-7.6%
4	GDYN	Grid Dynamics	22.9%	-58.0%
5	ARDX	Ardelyx	21.0%	19.5%
6	PACB	Pacific Biosciences of California	20.6%	27.9%
7	TWLO	Twilio	19.5%	24.8%
8	TVTX	Travere Therapeutics	18.6%	101.8%
9	BJRI	BJ's Restaurants	18.4%	-3.3%
10	BFAM	Bright Horizons Family Solutions	18.4%	-1.5%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	ATGE	Adtalem Global Education	-30.9%	7.9%
2	SVV	Savers Value Village	-30.4%	-10.1%
3	NWL	Newell Brands	-28.0%	-64.6%
4	SPSC	SPS Commerce	-20.8%	-55.3%
5	SOC	Sable Offshore	-18.5%	-54.3%
6	CPS	Cooper-Standard	-15.5%	122.9%
7	TBBK	Bancorp	-15.3%	24.2%
8	DXCM	DexCom	-14.6%	-25.1%
9	KOD	Kodiak Sciences	-13.9%	82.2%
10	AAUC	Allied Gold	-12.8%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	PUMP	ProPetro	64.5%	11.3%
2	VTYX	Ventyx Biosciences	46.8%	289.5%
3	INBX	Inhibrx Biosciences	42.5%	430.3%
4	RNA	Avidity Biosciences	42.1%	140.2%
5	GCI	Gannett	40.6%	4.7%
6	CSIQ	Canadian Solar	38.4%	86.7%
7	DYN	Dyne Therapeutics	31.9%	-4.2%
8	ZBIO	Zenas BioPharma	30.8%	281.6%
9	IMVT	Immunovant	30.3%	-0.4%
10	BBNX	Beta Bionics	29.9%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	LRN	Stride	-55.3%	-34.5%
2	NTLA	Intellia Therapeutics	-50.7%	8.2%
3	FMC	FMC	-50.2%	-67.4%
4	FI	Fiserv	-46.7%	-67.5%
5	VRNS	Varonis Systems	-43.5%	-20.7%
6	ATGE	Adtalem Global Education	-35.9%	7.9%
7	UAMY	United States Antimony	-32.8%	355.9%
8	SVV	Savers Value Village	-31.7%	-10.1%
9	NWL	Newell Brands	-31.7%	-64.6%
10	AKBA	Akebia Therapeutics	-27.1%	16.3%

Peer Comparisons for Stryker

Financials

	SYK	JNJ	MDT	ZBH	ITGR	CUPR	Median
Name	Stryker	Johnson .	Medtronic	Zimmer B.	Integer	Cuprina
Mkt Price	356.24	188.87	90.70	100.56	64.57	0.98	95.63
Mkt Cap	136.2	454.9	116.2	19.9	2.3	-	116.2
Rev LTM	24,381	92,149	34,200	7,834	1,831	-	24,381
Op Inc LTM	4,785	24,146	6,647	1,475	241	-	4,785
FCF LTM	4,073	18,679	5,303	1,384	120	-	4,073
FCF 3Y Avg	3,282	17,814	4,964	1,173	85	-	3,282
CFO LTM	4,832	24,204	7,146	1,663	204	-	4,832
CFO 3Y Avg	3,952	23,209	6,625	1,512	193	-	3,952

Growth & Margins

	SYK	JNJ	MDT	ZBH	ITGR	CUPR	Median
Name	Stryker	Johnson .	Medtronic	Zimmer B.	Integer	Cuprina
Rev Chg LTM	11.0%	5.1%	5.0%	4.1%	9.5%	-	5.1%
Rev Chg 3Y Avg	10.8%	6.1%	3.3%	4.3%	11.6%	-	6.1%
Rev Chg Q	10.2%	6.8%	8.4%	7.0%	8.4%	-	8.4%
QoQ Delta Rev Chg LTM	2.4%	1.7%	2.0%	1.8%	2.0%	-	2.0%
Op Mgn LTM	19.6%	26.2%	19.4%	18.8%	13.1%	-	19.4%
Op Mgn 3Y Avg	19.5%	26.4%	18.6%	19.2%	12.2%	-	19.2%
QoQ Delta Op Mgn LTM	0.0%	1.7%	-0.1%	-0.4%	0.0%	-	0.0%
CFO/Rev LTM	19.8%	26.3%	20.9%	21.2%	11.1%	-	20.9%
CFO/Rev 3Y Avg	17.8%	26.4%	20.2%	20.1%	11.6%	-	20.1%
FCF/Rev LTM	16.7%	20.3%	15.5%	17.7%	6.6%	-	16.7%
FCF/Rev 3Y Avg	14.7%	20.3%	15.1%	15.5%	5.0%	-	15.1%

Valuation

	SYK	JNJ	MDT	ZBH	ITGR	CUPR	Median
Name	Stryker	Johnson .	Medtronic	Zimmer B.	Integer	Cuprina
Mkt Cap	136.2	454.9	116.2	19.9	2.3	-	116.2
P/S	5.6	4.9	3.4	2.5	1.2	-	3.4
P/EBIT	28.5	14.0	18.2	16.1	14.3	-	16.1
P/E	46.3	18.1	24.9	24.2	26.1	-	24.9
P/CFO	28.2	18.8	16.3	12.0	11.1	-	16.3
Total Yield	3.1%	8.2%	7.1%	5.1%	3.8%	-	5.1%
Dividend Yield	0.9%	2.7%	3.1%	1.0%	0.0%	-	1.0%
FCF Yield 3Y Avg	2.6%	4.4%	4.5%	5.3%	2.5%	-	4.4%
D/E	0.1	0.1	0.2	0.4	0.6	-	0.2
Net D/E	0.1	0.1	0.2	0.4	0.6	-	0.2

Returns

	SYK	JNJ	MDT	ZBH	ITGR	CUPR	Median
Name	Stryker	Johnson .	Medtronic	Zimmer B.	Integer	Cuprina
1M Rtn	-2.8%	1.6%	-5.0%	1.4%	-37.4%	-11.1%	-3.9%
3M Rtn	-5.5%	13.7%	2.3%	11.2%	-39.4%	-88.1%	-1.6%
6M Rtn	-5.4%	22.9%	8.6%	-1.3%	-48.6%	-83.9%	-3.3%
12M Rtn	-2.1%	21.8%	4.0%	-5.4%	-48.9%	-	-2.1%
3Y Rtn	73.1%	21.4%	16.8%	-4.2%	3.8%	-	16.8%
1M Excs Rtn	-4.6%	-0.3%	-6.9%	-0.5%	-39.2%	-12.9%	-5.7%
3M Excs Rtn	-14.5%	3.2%	-6.1%	1.0%	-47.6%	-96.2%	-10.3%
6M Excs Rtn	-25.7%	2.6%	-11.7%	-21.6%	-68.9%	-104.2%	-23.6%
12M Excs Rtn	-17.1%	4.5%	-13.5%	-19.5%	-67.6%	-	-17.1%
3Y Excs Rtn	-18.0%	-58.4%	-61.2%	-86.7%	-71.0%	-	-61.2%

Comparison Analyses

	Title
0	How Does Stryker Stock Stack Up Against Its Peers?
1	Why SYK With 27% Upside May Beat BAX?
2	With 29% Gains On The Table, SYK May Outshine MDT
3	SYK Looks Stronger Than ZBH With 29% Return Potential
4	SYK Could Deliver 29% Returns And Outperform JNJ
5	Stryker vs. Vertex Pharmaceuticals: With Return Forecast Of 116%, Vertex Pharmaceuticals Is A Better Bet
6	Stryker vs. Zoetis: Both Seem Similar Bets
7	Stryker vs. Waste Management: With Return Forecast Of 20%, Stryker Is A Better Bet
8	Stryker vs. Intuit: With Return Forecast Of 24%, Intuit Is A Better Bet
9	Stryker vs. Booking Holdings: With Return Forecast Of 36%, Booking Holdings Is A Better Bet

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	10/31/2025	2/12/2025	2/14/2024	2/10/2023	2/11/2022	2/11/2021	2/6/2020
Key Financials
Total Revenue	24,381	22,595	20,498	18,449	17,108	14,351	14,884
EBITDA	5,926	5,716	4,952	4,109	3,677	3,052	3,683
Operating Income	4,785	4,666	3,924	3,111	2,687	2,240	2,905
Net Income	2,943	2,993	3,165	2,358	1,994	1,599	2,083
EPS	7.71	7.86	8.34	6.23	5.29	4.26	5.57
Growth Rates
Total Revenue Growth	11.0%	10.2%	11.1%	7.8%	19.2%	-3.6%	9.4%
EBITDA Growth	8.6%	15.4%	20.5%	11.7%	20.5%	-17.1%	12.2%
Operating Income Growth	8.2%	18.9%	26.1%	15.8%	20.0%	-22.9%	13.5%
Net Income Growth	-18.0%	-5.4%	34.2%	18.3%	24.7%	-23.2%	-41.4%
Margins
EBITDA Margin	24.3%	25.3%	24.2%	22.3%	21.5%	21.3%	24.7%
Operating Income Margin	19.6%	20.7%	19.1%	16.9%	15.7%	15.6%	19.5%
Net Income Margin	12.1%	13.2%	15.4%	12.8%	11.7%	11.1%	14.0%
Cash & Debt
Total Cash	3,343	4,493	3,053	1,928	3,019	3,024	4,425
Total Debt	16,595	13,597	12,995	13,048	12,479	13,991	11,090
Net Debt / (Cash)	13,252	9,104	9,942	11,120	9,460	10,967	6,665
Cash Flows
Net Cash from Operations	4,832	4,242	3,711	2,624	3,263	3,277	2,191
Free Cash from Operations	4,073	3,487	3,136	2,036	2,738	2,790	1,542
Returns to Shareholders
Dividends	1,268	1,219	1,139	1,051	950	863	778
Share Repurchases	-0	-0	-0	-0	-0	-0	307

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Filing Date	10/31/2025	8/1/2025	5/2/2025	2/12/2025	10/30/2024	7/31/2024	5/1/2024	2/14/2024	11/3/2023	8/4/2023	5/2/2023	2/10/2023
Key Financials Quarterly
Total Revenue	6,057	6,022	5,866	6,436	5,494	5,422	5,243	5,815	4,909	4,996	4,778	5,202
Ebitda	1,517	1,464	1,144	1,801	1,355	1,325	1,235	1,543	1,193	1,224	992	1,323
Operating Income	1,208	1,168	872	1,537	1,087	1,067	975	1,293	931	965	735	1,070
Net Income	859	884	654	546	834	825	788	1,143	692	738	592	563
EPS	2.25	2.32	1.71	1.43	2.18	2.17	2.07	3.01	1.82	1.95	1.56	1.48
Key Financials TTM
Total Revenue TTM	24,381	23,818	23,218	22,595	21,974	21,389	20,963	20,498	19,885	19,455	18,952	18,449
Ebitda TTM	5,926	5,764	5,625	5,716	5,458	5,296	5,195	4,952	4,732	4,593	4,398	4,109
Operating Income TTM	4,785	4,664	4,563	4,666	4,422	4,266	4,164	3,924	3,701	3,574	3,385	3,111
Net Income TTM	2,943	2,918	2,859	2,993	3,590	3,448	3,361	3,165	2,585	2,709	2,627	2,358
Growth Rates Quarterly
Total Revenue Growth	10.2%	11.1%	11.9%	10.7%	11.9%	8.5%	9.7%	11.8%	9.6%	11.2%	11.8%	10.7%
EBITDA Growth	12.0%	10.5%	-7.4%	16.7%	13.6%	8.3%	24.5%	16.6%	13.2%	19.0%	41.1%	24.6%
Operating Income Growth	11.1%	9.5%	-10.6%	18.9%	16.8%	10.6%	32.7%	20.8%	15.8%	24.4%	59.4%	29.9%
Net Income Growth	3.0%	7.2%	-17.0%	-52.2%	20.5%	11.8%	33.1%	103.0%	-15.2%	12.5%	83.3%	-15.0%
Margins Quarterly
EBITDA Margin	25.0%	24.3%	19.5%	28.0%	24.7%	24.4%	23.6%	26.5%	24.3%	24.5%	20.8%	25.4%
Operating Income Margin	19.9%	19.4%	14.9%	23.9%	19.8%	19.7%	18.6%	22.2%	19.0%	19.3%	15.4%	20.6%
Net Income Margin	14.2%	14.7%	11.1%	8.5%	15.2%	15.2%	15.0%	19.7%	14.1%	14.8%	12.4%	10.8%
Cash & Debt
Total Cash	3,343	2,464	2,409	4,493	4,684	1,957	2,407	3,053	1,936	1,478	1,757	1,928
Total Debt	16,595	16,580	16,781	13,597	15,484	12,222	12,865	12,995	12,690	12,947	13,061	13,048
Net Debt / (Cash)	13,252	14,116	14,372	9,104	10,800	10,265	10,458	9,942	10,754	11,469	11,304	11,120
Cash Flows Quarterly
FCF from Operations	1,540	1,111	250	1,931	1,474	633	204	1,528	1,050	688	445	1,003
Cash Flows TTM
FCF from Operations TTM	4,832	4,766	4,288	4,242	3,839	3,415	3,470	3,711	3,186	3,025	2,866	2,624
Returns to Shareholders Quarterly
Dividends	322	321	320	305	305	305	304	285	285	285	284	263
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	26.8%	25.6%	18.2%	54.8%	27.5%	28.8%	26.9%	41.0%	23.3%	23.8%	19.5%	24.4%
Return on Invested Capital (ROIC) TTM
ROIC TTM	28.0%	25.6%	23.8%	35.7%	30.0%	29.9%	28.9%	28.7%	23.4%	23.1%	22.8%	21.1%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
MedSurg and Neurotechnology	12,163	10,611	9,538	8,345
Orthopaedics	8,335				5,252
Orthopaedics and Spine		7,838	7,570	6,006
MedSurg					6,492
Neurotechnology & Spine					3,140
Total	20,498	18,449	17,108	14,351	14,884

Operating Income by Segment

$ Mil	2024	2023	2022	2021	2020
MedSurg and Neurotechnology	3,470	2,737	2,807	2,414
Orthopaedics	2,265				1,907
Inventory stepped up to fair value	0
Recall-related matters	-18	15	-103	-17	-192
Acquisition and integration-related charges	-20	-150	-585	-242	-275
Goodwill and other impairments	-36	-216
Regulatory and legal matters	-92	-76	2	-6	24
Medical device regulation	-96	-140	-107	-81	-62
Structural optimization and other special charges	-170	-349	-386	-458	-226
Amortization of intangible assets	-635	-627	-619	-472	-464
Corporate and Other	-780	-649	-605	-503	-480
Orthopaedics and Spine		2,296	2,180	1,588
MedSurg					1,642
Neurotechnology & Spine					839
Total	3,888	2,841	2,584	2,223	2,713

Assets by Segment

$ Mil	2024	2023	2022	2021	2020
MedSurg and Neurotechnology	20,804	18,487	15,218	15,250
Orthopaedics	18,023				9,085
Corporate and Other	1,085	931	1,264	990	1,370
Orthopaedics and Spine		17,466	18,149	18,090
MedSurg					12,066
Neurotechnology & Spine					7,646
Total	39,912	36,884	34,631	34,330	30,167

Price Behavior

Price Behavior

Market Price	$356.24
Market Cap ($ Bil)	136.2
First Trading Date	02/01/1988
Distance from 52W High	-11.5%
	50 Days	200 Days
DMA Price	$377.81	$378.88
DMA Trend	indeterminate	down
Distance from DMA	-5.7%	-6.0%
	3M	1YR
Volatility	18.5%	21.6%
Downside Capture	13.06	65.69
Upside Capture	-19.45	51.43
Correlation (SPY)	34.2%	63.9%

SYK Betas & Captures as of 10/31/2025

	1M	2M	3M	6M	1Y	3Y
Beta	0.25	0.37	0.56	0.70	0.70	0.76
Up Beta	1.68	1.69	1.47	0.88	0.73	0.81
Down Beta	0.77	0.51	0.92	0.95	0.79	0.83
Up Capture	-64%	-41%	-17%	27%	42%	39%
Bmk +ve Days	14	27	37	74	145	425
Stock +ve Days	10	18	28	59	119	393
Down Capture	-35%	33%	42%	78%	75%	88%
Bmk -ve Days	9	17	28	53	106	327
Stock -ve Days	13	26	37	68	132	360

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

1Y 5Y 10Y

Based On 1-Year Data

		Comparison of SYK With Other Asset Classes (Last 1Y)
	SYK	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	1.0%	-1.8%	18.5%	45.3%	3.1%	-4.4%	56.7%
Annualized Volatility	21.8%	17.0%	19.6%	19.9%	16.3%	18.1%	37.0%
Sharpe Ratio	-0.04	-0.27	0.74	1.77	0.00	-0.39	0.94
Correlation With Other Assets		60.7%	63.0%	6.3%	9.2%	63.7%	21.3%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of SYK With Other Asset Classes (Last 5Y)
	SYK	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	11.1%	7.6%	16.1%	15.6%	12.7%	5.9%	53.1%
Annualized Volatility	24.2%	14.6%	17.2%	15.6%	18.9%	19.2%	49.2%
Sharpe Ratio	0.42	0.35	0.77	0.80	0.56	0.23	0.80
Correlation With Other Assets		61.3%	62.8%	8.8%	11.2%	55.9%	22.5%

Based On 10-Year Data

		Comparison of SYK With Other Asset Classes (Last 10Y)
	SYK	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	15.5%	9.4%	14.5%	12.7%	5.2%	5.0%	81.9%
Annualized Volatility	25.9%	16.7%	18.0%	14.7%	17.7%	20.9%	56.2%
Sharpe Ratio	0.58	0.46	0.70	0.71	0.23	0.21	0.98
Correlation With Other Assets		67.3%	68.0%	4.6%	19.9%	60.4%	16.8%

Short Interest

Short Interest: As Of Date	10152025
Short Interest: Shares Quantity	3,749,178
Short Interest: % Change Since 9302025	-23.2%
Average Daily Volume	1,617,816
Days-to-Cover Short Interest	2.32
Basic Shares Quantity	382,400,000
Short % of Basic Shares	1.0%

Returns Analyses

	Title
0	How Low Can Stryker Stock Really Go?
1	Stryker Stock Return Comparison
2	[9/29/2021] Stryker (SYK) Stock Price Forecast: AI Forecasts SYK Stock Price To Be Around $275 In A Month (Up 2.7%)
3	Stryker Total Shareholder Return (TSR): -7.5% in 2022 and 6.3% 3-yr returns (above peer average)

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	10312025	10-Q 9/30/2025
6302025	8012025	10-Q 6/30/2025
3312025	5022025	10-Q 3/31/2025
12312024	2122025	10-K 12/31/2024
9302024	10302024	10-Q 9/30/2024
6302024	7312024	10-Q 6/30/2024
3312024	5012024	10-Q 3/31/2024
12312023	2142024	10-K 12/31/2023
9302023	11032023	10-Q 9/30/2023
6302023	8042023	10-Q 6/30/2023
3312023	5022023	10-Q 3/31/2023
12312022	2102023	10-K 12/31/2022
9302022	11012022	10-Q 9/30/2022
6302022	7272022	10-Q 6/30/2022
3312022	4292022	10-Q 3/31/2022
12312021	2112022	10-K 12/31/2021

Insider Activity

Expand for More

	Owner	Title	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	Menon Viju	Group President	8272025	Sell	390.61	500	195,305	4,886,922	Form
1	Fletcher Robert S	VP, Chief Legal Officer	8212025	Sell	393.07	1,785	701,630	4,110,333	Form
2	STRYKER RONDA E		8072025	Sell	374.99	34,911	13,091,276	1,270,165,003	Form
3	Berry William E Jr	VP, Chief Accounting Officer	5142025	Sell	388.56	1,241	482,202	1,100,789	Form
4	STRYKER RONDA E		5082025	Sell	374.76	18,362	6,881,330	1,347,883,283	Form

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Health Care Equipment Resources

MedTech Dive

MassDevice

Fierce Medical Devices

Medical Device and Diagnostic Industry

MD+DI

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Stryker (SYK)

Market Price (11/2/2025): $356.26 | Market Cap: $136.2 BilSector: Health Care | Industry: Health Care Equipment

Stryker (SYK)

Market Price (11/2/2025): $356.26Market Cap: $136.2 BilSector: Health CareIndustry: Health Care Equipment

Market Valuation & Key Metrics

SYK Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Stryker (SYK)

Interactive Breakdown

Better Bets than Stryker (SYK)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Stryker

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (11/2/2025): $356.26 | Market Cap: $136.2 Bil
Sector: Health Care | Industry: Health Care Equipment

Market Price (11/2/2025): $356.26
Market Cap: $136.2 Bil
Sector: Health Care
Industry: Health Care Equipment